BAYZF - Novartis/BeiGene's tislelizumab matches Bayer's Nexavar in survival benefit for liver cancer patients in trial
- BeiGene ( NASDAQ: BGNE ) and Novartis' ( NYSE: NVS ) tislelizumab met the main goal of being as good as Bayer's ( OTCPK:BAYZF ) ( OTCPK:BAYRY ) Nexavar (sorafenib) in improving overall survival (OS) of patients with a type of liver cancer in a phase 3 trial.
- The study, dubbed RATIONALE 301, evaluated tislelizumab against sorafenib as a first-line therapy in adult patients with unresectable hepatocellular carcinoma (HCC).
- More than 600 patients in the U.S., Europe, and Asia were in the study.
- BeiGene ( BGNE ) said that the the safety profile for tislelizumab was consistent with previous studies and no new safety signals were reported.
For further details see:
Novartis/BeiGene's tislelizumab matches Bayer's Nexavar in survival benefit for liver cancer patients in trial